Production (Stage)
Eledon Pharmaceuticals, Inc.
ELDN
$2.87
-$0.13-4.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 27.37% | 117.50% | 21.47% | 38.40% | 14.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.28% | 138.89% | 83.16% | 40.06% | -2.17% |
| Operating Income | -65.28% | -138.89% | -83.16% | -40.06% | 2.17% |
| Income Before Tax | 72.51% | -46.80% | 877.01% | 31.71% | -119.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 72.51% | -48.23% | 877.01% | 31.71% | -119.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 72.51% | -48.23% | 877.01% | 31.71% | -119.37% |
| EBIT | -65.28% | -138.89% | -83.16% | -40.06% | 2.17% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 89.31% | 40.37% | 417.03% | 78.26% | -4.51% |
| Normalized Basic EPS | 89.32% | 36.87% | 548.26% | 61.33% | -4.50% |
| EPS Diluted | 89.31% | 40.37% | 4.54% | 78.27% | -4.51% |
| Normalized Diluted EPS | 89.32% | 36.87% | 519.70% | 61.33% | -4.50% |
| Average Basic Shares Outstanding | 157.18% | 132.53% | 73.30% | 76.59% | 109.92% |
| Average Diluted Shares Outstanding | 157.18% | 132.53% | 85.09% | 76.59% | 109.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |